Literature DB >> 27068616

IgG4-related disease presenting as hypertrophic pachymeningitis and compressive optic neuropathy.

Gyuhwan Hwang1, So-Young Jin2, Hyun-Sook Kim3.   

Abstract

Entities:  

Keywords:  Hypertrophic pachymeningitis; IgG4-related disease; IgG4-related ophthalmic disease

Mesh：

Substances：

Year:  2016        PMID： 27068616     DOI： 10.1016/j.jbspin.2015.07.016

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN： 1297-319X            Impact factor:   4.929


× No keyword cloud information.
  5 in total

1.  Large dural-based mass with bony hyperostosis in a 16-year-old male: IgG4-related disease mimicking lymphoplasmacyte-rich meningioma.

Authors:  A Nambirajan; M Chand Sharma; K Garg; S Sriram; M Thej Boorgula; V Suri
Journal:  Childs Nerv Syst       Date:  2019-05-09       Impact factor: 1.475

Review 2.  Neurological Manifestations of IgG4-Related Disease.

Authors:  Bernardo Baptista; Alina Casian; Harsha Gunawardena; David D'Cruz; Claire M Rice
Journal:  Curr Treat Options Neurol       Date:  2017-04       Impact factor: 3.598

3.  Colon cancer and IgG4-related disease with orbital inflammation and bilateral optic perineuritis: A case report.

Authors:  Stephanie Lemaitre; Gemma Mateu Esquerda; Antoni Castro Guardiola; Jordi Teruel Agustin; Nicolae Sanda; Miguel González-Candial
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.889

4.  IgG4-related disease presenting as recurrent scleritis combined with optic neuropathy.

Authors:  Su Jin Kim; Seung Uk Lee; Min Seung Kang; Jung Hyo Ahn; Jonghoon Shin; Choul Yong Park; Ji Eun Lee
Journal:  BMC Ophthalmol       Date:  2021-01-05       Impact factor: 2.209

5.  Case Report: Diagnosis of Petrous Apex IgG4-Related Disease by Middle Cranial Fossa Craniotomy and Temporal Bone Biopsy.

Authors:  Louis Hofmeyr; Gerrida Herbst; Elias Pretorius; Brian Sarembock; Kathryn Taylor; David Roytowski
Journal:  Front Neurol       Date:  2022-06-09       Impact factor: 4.086
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.